BR0107683A - Drospirenona para terapia de reposição de hormÈnio - Google Patents

Drospirenona para terapia de reposição de hormÈnio

Info

Publication number
BR0107683A
BR0107683A BR0107683-3A BR0107683A BR0107683A BR 0107683 A BR0107683 A BR 0107683A BR 0107683 A BR0107683 A BR 0107683A BR 0107683 A BR0107683 A BR 0107683A
Authority
BR
Brazil
Prior art keywords
estrogen
hormone replacement
menopause
replacement therapy
drospirenone
Prior art date
Application number
BR0107683-3A
Other languages
English (en)
Inventor
Wolfgang Heil
Juergen Hilmann
Ralph Lipp
Rolf Schuermann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0107683(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0107683A publication Critical patent/BR0107683A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

"DROSPIRENONA PARA TERAPIA DE REPOSIçãO DE HORMÈNIO". Uma composição farmacêutica compreendendo como um primeiro ingrediente ativo um estrogênio, tal como estradiol ou valerato de estradiol, em quantidades suficientes para tratar distúrbios e sintomas associados com níveis endógenos deficientes de estrogênio em mulheres, e como um segundo ingrediente ativo 6<225>;7<225>;15<225>;16<225>-dimetileno-3-oxo-17<244>-preg- 4-eno-21,17-carbolactona (drospirenona, DRSP) em quantidades suficientes para proteger o endométrio dos efeitos adversos de estrogênio é útil para, entre outros, tratar mulheres em peri-menopausa, menopausa e pós-menopausa. Esta composição pode ser usada para terapia de reposição de hormónio e pode ser administrado como uma preparação farmacêutica de multifases. Esta terapia de combinação pode compreender administração contínua, seq³encial ou interrompida, ou combinações disso, de DRSP e estrogênio, cada um optativamente em forma micronizada.
BR0107683-3A 2000-01-18 2001-01-18 Drospirenona para terapia de reposição de hormÈnio BR0107683A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (en) 2000-01-18 2001-01-18 Drospirenone for hormone replacement therapy

Publications (1)

Publication Number Publication Date
BR0107683A true BR0107683A (pt) 2002-11-12

Family

ID=26071749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107683-3A BR0107683A (pt) 2000-01-18 2001-01-18 Drospirenona para terapia de reposição de hormÈnio

Country Status (30)

Country Link
EP (2) EP1611892B1 (pt)
JP (2) JP5128743B2 (pt)
KR (2) KR100913910B1 (pt)
CN (2) CN1395488A (pt)
AT (2) ATE305789T1 (pt)
AU (3) AU2541301A (pt)
BG (1) BG65849B1 (pt)
BR (1) BR0107683A (pt)
CA (1) CA2394165C (pt)
CY (1) CY1109567T1 (pt)
CZ (1) CZ20022411A3 (pt)
DE (2) DE60113809T2 (pt)
DK (2) DK1257280T3 (pt)
EE (1) EE05533B1 (pt)
ES (2) ES2247054T3 (pt)
HK (2) HK1047248B (pt)
HU (1) HUP0204291A3 (pt)
IL (3) IL150775A0 (pt)
ME (1) ME00292B (pt)
MX (1) MXPA02006613A (pt)
NO (1) NO335570B1 (pt)
NZ (1) NZ520630A (pt)
PL (1) PL201878B1 (pt)
PT (1) PT1611892E (pt)
RS (1) RS52149B (pt)
RU (2) RU2275198C2 (pt)
SI (2) SI1611892T1 (pt)
SK (2) SK287719B6 (pt)
WO (1) WO2001052857A1 (pt)
ZA (2) ZA200206551B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
WO2003006027A1 (en) 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
JP2005519961A (ja) * 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法
BR0309780A (pt) * 2002-04-26 2005-03-22 Schering Aktiengellschaft Tratamento da hipertensão em mulheres recebendo terapia de reposição hormonal
EP1558265B1 (en) * 2002-11-05 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Use of drospirenone for the treatment of hypertension
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
EP1980242B1 (en) * 2004-03-10 2010-08-11 Bayer Schering Pharma Aktiengesellschaft Liquid compositions as a micro-emulsion pre-concentrate comprising drospirenone moleculary dispersed
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2558076B1 (en) * 2010-04-15 2014-12-24 Bayer Intellectual Property GmbH Low-dosed solid oral dosage forms for hrt
CN102985070A (zh) 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的极低剂量的固体口服剂型
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN103957921A (zh) 2011-11-04 2014-07-30 拜耳医药股份有限公司 18-甲基-6，7-亚甲基-3-氧代-17-孕甾-4-烯-21，17β-碳内酯、包含所述化合物的药物制剂及其在治疗子宫内膜异位症中的用途
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US11253498B2 (en) 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
BR9710566A (pt) * 1996-07-26 1999-08-17 American Home Prod M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ

Also Published As

Publication number Publication date
JP5563227B2 (ja) 2014-07-30
IL150775A0 (en) 2003-02-12
KR20070051956A (ko) 2007-05-18
HUP0204291A3 (en) 2003-05-28
RU2402331C2 (ru) 2010-10-27
NZ520630A (en) 2004-09-24
NO20022966D0 (no) 2002-06-20
KR100747965B1 (ko) 2007-08-08
HUP0204291A2 (hu) 2003-04-28
HK1047248B (zh) 2005-12-30
EE05533B1 (et) 2012-04-16
PL201878B1 (pl) 2009-05-29
ME00292B (me) 2011-05-10
SK288129B6 (sk) 2013-10-02
DK1257280T3 (da) 2005-12-12
IL191131A0 (en) 2008-11-03
DE60139907D1 (de) 2009-10-22
MEP38008A (en) 2011-02-10
EP1611892B1 (en) 2009-09-09
ES2247054T3 (es) 2006-03-01
BG65849B1 (bg) 2010-03-31
EP1611892A2 (en) 2006-01-04
EP1257280B1 (en) 2005-10-05
EP1611892A3 (en) 2006-02-01
CZ20022411A3 (cs) 2003-02-12
ZA200206551B (en) 2006-04-29
SK287719B6 (en) 2011-07-06
RU2002122113A (ru) 2004-03-10
PT1611892E (pt) 2009-11-20
CN101934078A (zh) 2011-01-05
EE200200401A (et) 2003-10-15
CA2394165A1 (en) 2001-07-26
HK1082433A1 (en) 2006-06-09
AU2001225413B2 (en) 2005-06-23
YU54602A (sh) 2006-01-16
RU2005140938A (ru) 2007-07-10
DE60113809T2 (de) 2006-06-22
ATE305789T1 (de) 2005-10-15
DK1611892T3 (da) 2009-11-02
AU2005209600B2 (en) 2008-08-07
CN1395488A (zh) 2003-02-05
KR20020088066A (ko) 2002-11-25
ES2332226T3 (es) 2010-01-29
NO20022966L (no) 2002-09-18
ATE442147T1 (de) 2009-09-15
IL191131A (en) 2010-12-30
SK10322002A3 (sk) 2003-03-04
CY1109567T1 (el) 2014-08-13
JP2009120615A (ja) 2009-06-04
PL356987A1 (en) 2004-07-12
AU2541301A (en) 2001-07-31
CA2394165C (en) 2010-04-13
DE60113809D1 (de) 2006-02-16
IL150775A (en) 2008-08-07
JP2003520239A (ja) 2003-07-02
RS52149B (sr) 2012-08-31
KR100913910B1 (ko) 2009-08-26
MXPA02006613A (es) 2003-10-15
AU2005209600A1 (en) 2005-09-29
HK1047248A1 (en) 2003-02-14
WO2001052857A1 (en) 2001-07-26
EP1257280A1 (en) 2002-11-20
ZA200601285B (en) 2008-01-08
JP5128743B2 (ja) 2013-01-23
SI1257280T1 (sl) 2006-02-28
SI1611892T1 (sl) 2010-01-29
BG106915A (bg) 2003-04-30
NO335570B1 (no) 2014-12-29
RU2275198C2 (ru) 2006-04-27

Similar Documents

Publication Publication Date Title
BR0107683A (pt) Drospirenona para terapia de reposição de hormÈnio
MADANES et al. Danazol
ES2219673T3 (es) Dosificado posologico ciclofasico de hormonas que contienen una antiprogestina y una progestina.
KR20090080989A (ko) 여성 리비도의 유지 및/또는 증가를 위한 경구 치료요법을 위한 디에노게스트와 조합된 에스트라디올 발레레이트 또는 17β-에스트라디올의 용도
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
ES2338782T3 (es) Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados.
US20050222100A1 (en) Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
Wang et al. Standard and low-dose hormone therapy for postmenopausal women—focus on the breast
ES2293215T3 (es) Uso de una combinacion de un inhibidor de aromatasa, un progestageno y un estrogeno para el tratamiento de endometriosis.
Ohara Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma
ES2295050T3 (es) Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
Ciotta et al. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease
Shulman A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone
Rozenberg et al. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms
ES2316402T3 (es) Mesoprogestagenos (moduladores de los receptores de progesterona) como un componente de composiciones para la hormonoterapia restitutiva (hrt).
Kaunitz The role of androgens in menopausal hormonal replacement
HRP20070360B1 (hr) Drospirenon za hormonsku nadomjesnu terapiju
KR19990087672A (ko) 호르몬 대체 치료를 위한 순차적 에스트로겐/프로게스테론길항제 배합
HRP20020666A8 (en) Drospirenone for hormone replacement therapy
Dören et al. Therapeutic value and long-term safety of pulsed estrogen therapy
US7629334B1 (en) Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
Marslew et al. 92010558 Desogestrel in hormone replacement therapy: Long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding
Smith et al. 92007299 Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system
TH134365B (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน
TH134365A (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020070067652 DE 23/05/2007 COM BASE NO DISPOSTO NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE O PEDIDO JA SE ENCONTRA ANALISADO.

B153 Others concerning applications: republication [chapter 15.33 patent gazette]

Free format text: REPUBLICADO O DESPACHO 15.7 PUBLICADO NA RPI 1925 DE 27/11/2007, HAJA VISTA EXISTENCIA DE ERRO MATERIAL NO TEOR DO DESPACHO. ONDE SE LE " UMA VEZ QUE O PEDIDO JA SE ENCONTRA ANALISADO", LEIA-SE " UMA VEZ QUE O PEDIDO ENCONTRA-SE EM EXAME, SENDO DESNECESSARIO REQUERIMENTO DE EXAME PRIORITARIO PARA O MESMO".

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO DISPOSTO NOS ARTS. 8O, 11 E 13 DA LEI 9.279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: NOME ALTERADO DE: SCHERING AKTIENGESELLSCHAFT